IL13 and atopic eczema: Dupilumab is a monoclonal antibody that acts as a dual inhibitor to IL-4 and IL-13 cytokine signaling and has been approved by the FDA since 2017 for the treatment of atopic dermatitis with subsequent indications for asthma and nasal polyps.